Journal Article

Antibodies against glycoprotein 2 are novel markers of intestinal inflammation in patients with an ileal pouch

Lael Werner, Andreas Sturm, Dirk Roggenbuck, Lior Yahav, Tanir Zion, Elhanan Meirowithz, Amos Ofer, Hanan Guzner-Gur, Hagit Tulchinsky and Iris Dotan

in Journal of Crohn's and Colitis

Volume 7, issue 11, pages e522-e532
Published in print December 2013 | ISSN: 1873-9946
Published online December 2013 | e-ISSN: 1876-4479 | DOI: https://dx.doi.org/10.1016/j.crohns.2013.03.009
Antibodies against glycoprotein 2 are novel markers of intestinal inflammation in patients with an ileal pouch

Show Summary Details

Preview

Abstract

Background and aims: The Crohn's disease (CD)-specific pancreatic auto-antibodies (PAB), have been recently identified to target glycoprotein 2 (GP2). Pouchitis is an inflammation of the small bowel developing in up to 60% of ulcerative colitis patients undergoing proctocolectomy and ileal pouch anal anastomosis. Occurrence of CD-specific antibodies was reported to be a predictor of pouchitis. We aimed to assess the prevalence of anti-GP2 antibodies (anti-GP2) in the serum and feces of pouch patients and to correlate them with clinical parameters. Furthermore, we examined mucosal expression of the GP2 protein in the pouch.

Methods: Pouch patients were prospectively recruited and checked for clinical, endoscopic, and laboratory markers of inflammation. IgG and IgA anti-GP2 levels in serum and fecal samples were determined using ELISA. GP2 protein was assessed by immunohistochemistry.

Results: Anti-GP2 was elevated in both serum and fecal samples of patients with inflamed compared to those with non-inflamed pouches and patients with familial-adenomatous polyposis after surgery (p < 0.05, respectively). Moreover, patients with CD-like complications exhibited significantly higher anti-GP2 titers than those without CD-like complications (p ≤ 0.01). High levels of anti-GP2 correlated with more frequent bowel movements per day and with the presence of at least one anti-glycan antibody (p ≤ 0.05). GP2 itself was more abundant in the mucosa of patients with chronic pouchitis.

Conclusions: Anti-GP2 exists in the serum and feces of pouch patients and correlates with pouch inflammation, and presence of other serological markers. Thus, anti-GP2 may contribute to better stratification of pouchitis, more-so when the inflammation exhibits CD-like complications.

Keywords: Pouchitis; Glycoprotein 2; Anti-GP2; Serological markers; IPAA

Journal Article.  5508 words.  Illustrated.

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content. subscribe or login to access all content.